Cells (Apr 2022)

MicroRNA-like snoRNA-Derived RNAs (sdRNAs) Promote Castration-Resistant Prostate Cancer

  • Alexander B. Coley,
  • Ashlyn N. Stahly,
  • Mohan V. Kasukurthi,
  • Addison A. Barchie,
  • Sam B. Hutcheson,
  • Dominika Houserova,
  • Yulong Huang,
  • Brianna C. Watters,
  • Valeria M. King,
  • Meghan A. Dean,
  • Justin T. Roberts,
  • Jeffrey D. DeMeis,
  • Krisha V. Amin,
  • Cameron H. McInnis,
  • Noel L. Godang,
  • Ryan M. Wright,
  • David F. Haider,
  • Neha B. Piracha,
  • Cana L. Brown,
  • Zohaib M. Ijaz,
  • Shengyu Li,
  • Yaguang Xi,
  • Oliver G. McDonald,
  • Jingshan Huang,
  • Glen M. Borchert

DOI
https://doi.org/10.3390/cells11081302
Journal volume & issue
Vol. 11, no. 8
p. 1302

Abstract

Read online

We have identified 38 specifically excised, differentially expressed snoRNA fragments (sdRNAs) in TCGA prostate cancer (PCa) patient samples as compared to normal prostate controls. SnoRNA-derived fragments sdRNA-D19b and -A24 emerged among the most differentially expressed and were selected for further experimentation. We found that the overexpression of either sdRNA significantly increased PC3 (a well-established model of castration-resistant prostate cancer (CRPC)) cell proliferation, and that sdRNA-D19b overexpression also markedly increased the rate of PC3 cell migration. In addition, both sdRNAs provided drug-specific resistances with sdRNA-D19b levels correlating with paclitaxel resistance and sdRNA-24A conferring dasatinib resistance. In silico and in vitro analyses revealed that two established PCa tumor suppressor genes, CD44 and CDK12, represent targets for sdRNA-D19b and sdRNA-A24, respectively. This outlines a biologically coherent mechanism by which sdRNAs downregulate tumor suppressors in AR-PCa to enhance proliferative and metastatic capabilities and to encourage chemotherapeutic resistance. Aggressive proliferation, rampant metastasis, and recalcitrance to chemotherapy are core characteristics of CRPC that synergize to produce a pathology that ranks second in cancer-related deaths for men. This study defines sdRNA-D19b and -A24 as contributors to AR-PCa, potentially providing novel biomarkers and therapeutic targets of use in PCa clinical intervention.

Keywords